AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

In September, AstraZeneca's subsidiary MedImmune gained approval for a live H1N1 Flumist vaccine. Further afield, Beijing-based Sinovac Biotech also received approval for an H1N1 vaccine from the ...

If you’re on the fence about investing in AstraZeneca PLC, Merck & Co. or Inc. because you ... Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, ...

But next year, you could get vaccinated for the flu at home. Just last month, the FDA approved FluMist, a nasal-spray flu ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses.

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 billion. However many analysts felt the company had paid far too much ...

The WHO declared mpox a global public health emergency for the second time in two years in August after a new variant of the virus, called clade Ib, spread from the Democratic Republic of Congo to ...

The Biden administration gave Israel 30 days to increase the flow of aid, warning that aid shipments into Gaza in September had reached an alarmingly low level. By Liam Stack and Aaron Boxerman ...